Lancet Neurol
Published

Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.

Authors

Suvankar Pal, Jeremy Chataway, Robert Swingler, Malcolm R Macleod, Neil O Carragher, Giles Hardingham, Bhuvaneish Thangaraj Selvaraj, Colin Smith, Charis Wong, Judith Newton, Dawn Lyle, Amy Stenson, Rachel S Dakin, Amarachi Ihenacho, Shuna Colville, Arpan R Mehta, Nigel Stallard, James R Carpenter, Richard A Parker, Catriona Keerie, Christopher J Weir, Bruce Virgo, Stevie Morris, Nicola Waters, Beverley Gray, Donald MacDonald, Euan MacDonald, Mahesh K B Parmar, Siddharthan Chandran,
Read More

Abstract

Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of effective disease-modifying therapies. The MND SMART trial aims to test the safety and efficacy of promising interventions efficiently and definitively against a single contemporaneous placebo control group. We now report results of the stage two interim analysis for memantine and trazodone.

PMID:39307154 | DOI:10.1016/S1474-4422(24)00326-0

UK DRI Authors

Suvankar Pal profile

Prof Suvankar Pal

Group Leader

Clinically active academic neurologist specialising in motor neuron disease

Prof Suvankar Pal
Giles Hardingham

Prof Giles Hardingham

Centre Director & Directors' Counsel

Studying astrocytes to better understand their role in helping maintain a healthy brain

Prof Giles Hardingham
Colin Smith profile

Prof Colin Smith

Chair of Neuropathology; Director of Centre for Clinical Brain Sciences

Prof Colin Smith
Siddharthan Chandran

Prof Siddharthan Chandran

Director & CEO

Dissecting a genetic cause of ALS and FTD and identifying ways to help protect neurons

Prof Siddharthan Chandran